The TCR.strong metric has been predicted using a CD4+ T cell system and then applied at the bulk tumor level, therefore the extent to which this metric is modified in CD8+ versus CD4+ T cells (or potentially other cells) remains to be determined. The gene discussed is CD8A; the disease is neoplasm.